Search - tctmd.com

Displaying 1 - 20 of 4101

Sort: Relevancy | Date

STAR Trial Gives Insight Into Two-Stage CTO PCI in Complex Patients

News Daily News

STAR Trial Gives Insight Into Two-Stage CTO PCI in Complex Patients

Yael L. Maxwell

December 05, 2025

TCTMD’s Top 10 Most Popular Stories for November 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2025

December 01, 2025

November 2025 Dispatch for the CV Team

News Opinion CV Team Dispatch

November 2025 Dispatch for the CV Team

November 24, 2025

Long-Awaited CREST-2 Results Bolster Stents for Asymptomatic Carotid Stenosis

News Daily News

Long-Awaited CREST-2 Results Bolster Stents for Asymptomatic Carotid Stenosis

November 21, 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

News Conference News AHA 2025

Prasugrel May Be Better Than Ticagrelor After PCI for Diabetes Patients With MVD

November 13, 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

News Conference News AHA 2025

CELEBRATE: Zalunfiban, a Novel Glycoprotein IIb/IIIa Inhibitor, Helps in STEMI

Michael O'Riordan

November 11, 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

News Conference News AHA 2025

Anticoagulation Alone Is Best in AF Patients a Year or More Out From PCI

November 09, 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

News Conference News AHA 2025

One Month of Dual Antithrombotic Therapy May Be Enough After PCI in AF Patients

November 08, 2025

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

News Conference News TCT 2025

At 3 Years, DCBs Still Less Safe Than DES in De Novo CAD: REC-CAGEFREE I

Yael L. Maxwell

November 07, 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

November 03, 2025

TCTMD’s Top 10 Most Popular Stories for October 2025

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for October 2025

November 03, 2025

News Industry News

SMT’s Supraflex Cruz Shows Consistent and Robust Clinical Outcomes Across Key Global Studies Presented at TCT 2025

October 29, 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Stent’s Benefits Seen Over Time

News Conference News TCT 2025

INFINITY-SWEDEHEART: ‘Unlocking’ Device Bests DES Over Time

Michael O'Riordan

October 29, 2025

iFR-Guided Immediate PCI Not Superior to Deferred CMR-Guided Strategy in STEMI

News Conference News TCT 2025

iFR-Guided Immediate PCI Not Superior to Deferred CMR-Guided Strategy in STEMI

Yael L. Maxwell

October 28, 2025

PROCTOR: PCI of Failed Bypass Grafts Tops Native-Vessel PCI, With Caveats

News Conference News TCT 2025

PROCTOR: PCI of Failed Bypass Grafts Tops Native-Vessel PCI, With Caveats

October 28, 2025

STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus

News Conference News TCT 2025

STRIVE: Low-Dose Alteplase Ineffective in STEMI Patients With Large Thrombus

Michael O'Riordan

October 28, 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

News Conference News TCT 2025

Sirolimus-Coated Balloon Meets Mark in De Novo Lesions and ISR: SELUTION

Michael O'Riordan

October 26, 2025

Trials Bolster Alternatives to Intravascular Lithotripsy for Calcified Lesions

News Conference News TCT 2025

Trials Bolster Alternatives to Intravascular Lithotripsy for Calcified Lesions

October 26, 2025

What’s Going to Be Hot at TCT 2025

News Opinion Editor's Corner TCT 2025

What’s Going to Be Hot at TCT 2025

Michael O'Riordan

October 09, 2025

CELEBRATE: Prehospital Platelet Inhibitor Zalunfiban Hits Mark in STEMI

News Daily News

CELEBRATE: Prehospital Platelet Inhibitor Zalunfiban Hits Mark in STEMI

Michael O'Riordan

September 23, 2025

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.